CA2535506A1 - Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire - Google Patents

Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire Download PDF

Info

Publication number: CA2535506A1
Authority: CA; Canada
Prior art keywords: selenium; composition; breast; brca1; ovarian cancer
Prior art date: 2003-08-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002535506A

Other languages

English (en)

Inventor

Jan Lubinsky

Steven Narod

Stanislaw Zajaczek

Elzbieta Kowalska

Bohdan Gorski

Tomasz Huzarski

Tomasz Byrski

Jacek Gronwald

Jowita Huzarska

Barbara Gawronska-Szklarz

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pomeranian Academy of Medicine

Original Assignee

Pomeranian Academy of Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-11

Filing date

2004-08-10

Publication date

2005-02-17

2004-08-10 Application filed by Pomeranian Academy of Medicine filed Critical Pomeranian Academy of Medicine

2005-02-17 Publication of CA2535506A1 publication Critical patent/CA2535506A1/fr

Status Abandoned legal-status Critical Current

Links

208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 38
206010006187 Breast cancer Diseases 0.000 title claims abstract description 37
210000000481 breast Anatomy 0.000 title claims abstract description 33
206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 32
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
206010033128 Ovarian cancer Diseases 0.000 title claims description 16
239000011669 selenium Substances 0.000 claims abstract description 86
229910052711 selenium Inorganic materials 0.000 claims abstract description 84
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 81
101150072950 BRCA1 gene Proteins 0.000 claims abstract description 34
230000035772 mutation Effects 0.000 claims abstract description 34
150000001875 compounds Chemical class 0.000 claims abstract description 21
239000000969 carrier Substances 0.000 claims abstract description 19
150000003839 salts Chemical class 0.000 claims abstract description 17
238000000034 method Methods 0.000 claims abstract description 16
230000002265 prevention Effects 0.000 claims abstract description 8
FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 claims abstract description 5
FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims abstract description 5
QYHFIVBSNOWOCQ-UHFFFAOYSA-N selenic acid Chemical compound O[Se](O)(=O)=O QYHFIVBSNOWOCQ-UHFFFAOYSA-N 0.000 claims abstract description 5
ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 claims abstract description 5
235000016491 selenocysteine Nutrition 0.000 claims abstract description 5
229940055619 selenocysteine Drugs 0.000 claims abstract description 5
RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims abstract description 4
RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 claims abstract description 4
229960002718 selenomethionine Drugs 0.000 claims abstract description 4
UEQANLFPOFICBH-UHFFFAOYSA-N methylseleninic acid Chemical compound C[Se](O)=O UEQANLFPOFICBH-UHFFFAOYSA-N 0.000 claims abstract description 3
229940091258 selenium supplement Drugs 0.000 claims description 83
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
239000000203 mixture Substances 0.000 claims description 34
206010028980 Neoplasm Diseases 0.000 claims description 27
239000000243 solution Substances 0.000 claims description 16
BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical group [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 13
229960001471 sodium selenite Drugs 0.000 claims description 13
235000015921 sodium selenite Nutrition 0.000 claims description 13
239000011781 sodium selenite Substances 0.000 claims description 13
206010071980 BRCA1 gene mutation Diseases 0.000 claims description 9
108700040618 BRCA1 Genes Proteins 0.000 claims description 7
239000007864 aqueous solution Substances 0.000 claims description 7
229940065287 selenium compound Drugs 0.000 claims description 6
150000003343 selenium compounds Chemical class 0.000 claims description 6
108020004414 DNA Proteins 0.000 claims description 5
229930014626 natural product Natural products 0.000 claims description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 4
235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 4
240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 4
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
239000012153 distilled water Substances 0.000 claims description 4
238000001514 detection method Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000000644 isotonic solution Substances 0.000 claims description 3
SPVXKVOXSXTJOY-UHFFFAOYSA-N selane Chemical class [SeH2] SPVXKVOXSXTJOY-UHFFFAOYSA-N 0.000 claims description 2
150000003342 selenium Chemical class 0.000 claims description 2
239000002904 solvent Substances 0.000 claims 2
241000196324 Embryophyta Species 0.000 claims 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
229910018143 SeO3 Inorganic materials 0.000 claims 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
229940082569 selenite Drugs 0.000 claims 1
MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 claims 1
239000011780 sodium chloride Substances 0.000 claims 1
102000036365 BRCA1 Human genes 0.000 abstract description 30
108700020463 BRCA1 Proteins 0.000 abstract description 28
-1 selenomethylcysteine Chemical compound 0.000 abstract description 3
125000003748 selenium group Chemical group *[Se]* 0.000 abstract description 2
201000011510 cancer Diseases 0.000 description 17
230000009469 supplementation Effects 0.000 description 17
210000004027 cell Anatomy 0.000 description 13
208000037088 Chromosome Breakage Diseases 0.000 description 8
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
239000011593 sulfur Substances 0.000 description 7
229910052717 sulfur Inorganic materials 0.000 description 7
RVIXKDRPFPUUOO-UHFFFAOYSA-N dimethylselenide Chemical compound C[Se]C RVIXKDRPFPUUOO-UHFFFAOYSA-N 0.000 description 6
JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 6
108010006654 Bleomycin Proteins 0.000 description 5
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 5
229960001561 bleomycin Drugs 0.000 description 5
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 5
230000002113 chemopreventative effect Effects 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
108700010154 BRCA2 Genes Proteins 0.000 description 4
101150008921 Brca2 gene Proteins 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
108700024394 Exon Proteins 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000003814 drug Substances 0.000 description 3
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
150000003346 selenoethers Chemical class 0.000 description 3
102000052609 BRCA2 Human genes 0.000 description 2
108700020462 BRCA2 Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
JMQMNWIBUCGUDO-UHFFFAOYSA-N L-Djenkolic acid Natural products OC(=O)C(N)CSCSCC(N)C(O)=O JMQMNWIBUCGUDO-UHFFFAOYSA-N 0.000 description 2
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
JMQMNWIBUCGUDO-WHFBIAKZSA-N L-djenkolic acid Chemical compound OC(=O)[C@@H](N)CSCSC[C@H](N)C(O)=O JMQMNWIBUCGUDO-WHFBIAKZSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
XDSSPSLGNGIIHP-VKHMYHEASA-N Se-methyl-L-selenocysteine Chemical compound C[Se]C[C@H]([NH3+])C([O-])=O XDSSPSLGNGIIHP-VKHMYHEASA-N 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
230000004075 alteration Effects 0.000 description 2
AKLNLVOZXMQGSI-UHFFFAOYSA-N bufetolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1OCC1OCCC1 AKLNLVOZXMQGSI-UHFFFAOYSA-N 0.000 description 2
UWZXJRBXKTZILP-UHFFFAOYSA-L calcium;selenite Chemical compound [Ca+2].[O-][Se]([O-])=O UWZXJRBXKTZILP-UHFFFAOYSA-L 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
230000002559 cytogenic effect Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
SMVMOIXTOKYXAN-UHFFFAOYSA-L dilithium;selenite Chemical compound [Li+].[Li+].[O-][Se]([O-])=O SMVMOIXTOKYXAN-UHFFFAOYSA-L 0.000 description 2
201000010099 disease Diseases 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
201000002628 peritoneum cancer Diseases 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
WBRSXICUEVGXAB-UHFFFAOYSA-N selenonic acid Chemical compound O[SeH](=O)=O WBRSXICUEVGXAB-UHFFFAOYSA-N 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
PFNQVRZLDWYSCW-UHFFFAOYSA-N (fluoren-9-ylideneamino) n-naphthalen-1-ylcarbamate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1=NOC(=O)NC1=CC=CC2=CC=CC=C12 PFNQVRZLDWYSCW-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
VKUCHMVHDHABFA-UHFFFAOYSA-N 2-amino-2-(sulfanylmethyl)butanoic acid Chemical compound CCC(N)(CS)C(O)=O VKUCHMVHDHABFA-UHFFFAOYSA-N 0.000 description 1
YVYYJWYPTKQLNY-UHFFFAOYSA-N 2-amino-2-sulfanyloctanoic acid Chemical compound CCCCCCC(N)(S)C(O)=O YVYYJWYPTKQLNY-UHFFFAOYSA-N 0.000 description 1
FVNKWWBXNSNIAR-UHFFFAOYSA-N 2-amino-3-(2-sulfanylidene-1,3-dihydroimidazol-4-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CNC(S)=N1 FVNKWWBXNSNIAR-UHFFFAOYSA-N 0.000 description 1
ROYIRMLRQNTCAO-UHFFFAOYSA-N 2-amino-4-ethyl-2-sulfanylhexanoic acid Chemical compound CCC(CC)CC(N)(S)C(O)=O ROYIRMLRQNTCAO-UHFFFAOYSA-N 0.000 description 1
ZJFISDZECFYPMA-UHFFFAOYSA-N 2-amino-4-methyl-2-sulfanylpentanoic acid Chemical compound CC(C)CC(N)(S)C(O)=O ZJFISDZECFYPMA-UHFFFAOYSA-N 0.000 description 1
BZMBZISTEDVTDS-UHFFFAOYSA-N 2-amino-5-methyl-2-sulfanylhexanoic acid Chemical compound CC(C)CCC(N)(S)C(O)=O BZMBZISTEDVTDS-UHFFFAOYSA-N 0.000 description 1
PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
206010071981 BRCA2 gene mutation Diseases 0.000 description 1
108091060290 Chromatid Proteins 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
108010022355 Fibroins Proteins 0.000 description 1
238000002738 Giemsa staining Methods 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
RWSXRVCMGQZWBV-UHFFFAOYSA-N L-Glutathione (reduced) Chemical compound OC(=O)C(N)CCC(=O)NC(CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-UHFFFAOYSA-N 0.000 description 1
ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
ZNXZGRMVNNHPCA-UHFFFAOYSA-N Pantetheine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000004756 chromatid Anatomy 0.000 description 1
230000005886 chromosome breakage Effects 0.000 description 1
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
239000005516 coenzyme A Substances 0.000 description 1
229940093530 coenzyme a Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
108010016616 cysteinylglycine Proteins 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000007423 decrease Effects 0.000 description 1
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
VZZSRKCQPCSMRS-UHFFFAOYSA-N dipotassium;selenium(2-) Chemical compound [K+].[K+].[Se-2] VZZSRKCQPCSMRS-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
230000004731 environmental carcinogenesis Effects 0.000 description 1
201000007741 female breast cancer Diseases 0.000 description 1
201000002276 female breast carcinoma Diseases 0.000 description 1
102000034240 fibrous proteins Human genes 0.000 description 1
108091005899 fibrous proteins Proteins 0.000 description 1
231100000024 genotoxic Toxicity 0.000 description 1
230000001738 genotoxic effect Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229960001913 mecysteine Drugs 0.000 description 1
230000031864 metaphase Effects 0.000 description 1
230000001035 methylating effect Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000007427 paired t-test Methods 0.000 description 1
ZNXZGRMVNNHPCA-VIFPVBQESA-N pantetheine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-VIFPVBQESA-N 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
102200067153 rs28897672 Human genes 0.000 description 1
238000001629 sign test Methods 0.000 description 1
201000008261 skin carcinoma Diseases 0.000 description 1
229960001881 sodium selenate Drugs 0.000 description 1
235000018716 sodium selenate Nutrition 0.000 description 1
239000011655 sodium selenate Substances 0.000 description 1
VPQBLCVGUWPDHV-UHFFFAOYSA-N sodium selenide Chemical compound [Na+].[Na+].[Se-2] VPQBLCVGUWPDHV-UHFFFAOYSA-N 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
NJRXVEJTAYWCQJ-UHFFFAOYSA-N thiomalic acid Chemical compound OC(=O)CC(S)C(O)=O NJRXVEJTAYWCQJ-UHFFFAOYSA-N 0.000 description 1
210000004906 toe nail Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA002535506A 2003-08-11 2004-08-10 Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire Abandoned CA2535506A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PLP.361597		2003-08-11
PL361597A PL214402B1 (pl)	2003-08-11	2003-08-11	Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
PCT/PL2004/000063 WO2005013951A2 (fr)	2003-08-11	2004-08-10	Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire

Publications (1)

Publication Number	Publication Date
CA2535506A1 true CA2535506A1 (fr)	2005-02-17

Family

ID=34132453

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002535506A Abandoned CA2535506A1 (fr)	2003-08-11	2004-08-10	Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire

Country Status (10)

Country	Link
EP (1)	EP1660060A2 (fr)
JP (1)	JP2007502270A (fr)
KR (1)	KR20060066719A (fr)
CN (1)	CN1835740A (fr)
AU (1)	AU2004263070A1 (fr)
CA (1)	CA2535506A1 (fr)
EA (1)	EA200600386A1 (fr)
PL (1)	PL214402B1 (fr)
WO (1)	WO2005013951A2 (fr)
ZA (1)	ZA200602081B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2581101A1 (fr) *	2004-09-21	2006-03-30	Velacor Therapeutics Pty Ltd	Selenium inorganique pour le traitement du cancer
CN101874120B (zh) *	2007-03-26	2015-01-14	解码遗传学私营有限责任公司	作为用于乳腺癌风险评估、诊断、预后和治疗的标记的chr2和chr16的遗传性变型
CN100548311C (zh)	2007-06-13	2009-10-14	中国科学技术大学	硒代硫酸钠在制备临床补硒和治疗癌症药物中的应用及快速制备方法
WO2009043106A1 (fr) *	2007-10-03	2009-04-09	Velacor Therapeutics Pty Ltd	Sélénium inorganique et angiogenèse
US20110105342A1 (en) *	2008-03-13	2011-05-05	Jan Lubinski	Method for determining reduced predisposition to cancer based on genetic profile
KR101026291B1 (ko) *	2008-06-30	2011-03-31	주식회사 태강	SeO2 doped W-Mo-Li 화합물을 함유한 항암제 조성물
GB0916010D0 (en) *	2009-09-11	2009-10-28	Isis Innovation	JMJD2 demethylase inhibitors
WO2012067525A1 (fr)	2010-11-18	2012-05-24	Pomorski Uniwersytet Medyczny	Génotypes et niveau de sélénium utilisés en tant que marqueurs du risque de cancer du sein/ovaire chez des sujets porteurs d'une mutation du gène brca1
CN103608006B (zh)	2011-04-01	2017-07-07	伊亚索梅股份公司	包含n‑乙酰基‑l‑半胱氨酸的组合及其用途
CN114533753A (zh) *	2013-03-15	2022-05-27	全技术公司	含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
AU2014386236B2 (en) *	2014-03-14	2019-07-11	Alltech, Inc.	Compositions of selenoorganic compounds and methods of use thereof
US20240299401A1 (en) *	2020-10-06	2024-09-12	The Penn State Research Foundation	Novel redox-based therapeutic approach for treatment of cancer
US12005092B2 (en) *	2021-12-22	2024-06-11	Laura Mann Kevehazi	Herbal composition for breast cancer prevention
PL442921A1 (pl) *	2022-11-23	2024-05-27	Read-Gene Spółka Akcyjna	Obniżanie ryzyka zgonów u kobiet z dziedziczną predyspozycją do raka piersi

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19825746A1 (de) *	1998-06-09	1999-12-16	Biosyn Arzneimittel Gmbh	Kombination von Selen-haltigen Verbindungen mit Zytostatika

2003
- 2003-08-11 PL PL361597A patent/PL214402B1/pl unknown
2004
- 2004-08-10 EP EP04775169A patent/EP1660060A2/fr not_active Withdrawn
- 2004-08-10 CN CNA2004800231246A patent/CN1835740A/zh active Pending
- 2004-08-10 JP JP2006523155A patent/JP2007502270A/ja not_active Withdrawn
- 2004-08-10 AU AU2004263070A patent/AU2004263070A1/en not_active Abandoned
- 2004-08-10 CA CA002535506A patent/CA2535506A1/fr not_active Abandoned
- 2004-08-10 KR KR1020067002810A patent/KR20060066719A/ko not_active Ceased
- 2004-08-10 EA EA200600386A patent/EA200600386A1/ru unknown
- 2004-08-10 WO PCT/PL2004/000063 patent/WO2005013951A2/fr not_active Ceased
2006
- 2006-03-10 ZA ZA200602081A patent/ZA200602081B/en unknown

Also Published As

Publication number	Publication date
ZA200602081B (en)	2007-05-30
KR20060066719A (ko)	2006-06-16
EA200600386A1 (ru)	2006-12-29
WO2005013951A3 (fr)	2005-09-15
PL214402B1 (pl)	2013-07-31
JP2007502270A (ja)	2007-02-08
PL361597A1 (en)	2005-02-21
CN1835740A (zh)	2006-09-20
WO2005013951A2 (fr)	2005-02-17
EP1660060A2 (fr)	2006-05-31
AU2004263070A1 (en)	2005-02-17

Publication	Publication Date	Title
CA2535506A1 (fr)	2005-02-17	Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire
Prasad et al.	2002	Zinc in cancer prevention
Mariani et al.	2008	Effects of zinc supplementation on antioxidant enzyme activities in healthy old subjects
Prasad	2014	Zinc: an antioxidant and anti-inflammatory agent: role of zinc in degenerative disorders of aging
Brewer et al.	2020	Essential and toxic trace elements and vitamins in human health
KR102090836B1 (ko)	2020-03-18	세포 정제를 촉진하기 위한 경구 제제
AU715430B2 (en)	2000-02-03	Carotenoid-nicotinamide-zinc compositions and methods of treatment using same
US20050069594A1 (en)	2005-03-31	Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer
Kumar et al.	2016	Zinc deficiency and its effect on the brain: an update
EA030339B1 (ru)	2018-07-31	Композиция водорастворимых селеногликопротеинов и способ ее получения
Hurley et al.	2012	Trace elements in man and animals 6
MXPA06001632A (en)	2007-04-10	Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer
Scott et al.	2024	Safety Assessment of Zinc Salts as Used in Cosmetics
Fouad et al.	2013	A randomized, double-blind clinical study on the safety and tolerability of an iron multi-amino acid chelate preparation in premenopausal women
Jachimowicz-Rogowska et al.	2022	The most commonly used diet supplements for hair, skin and nails in the opinion of pharmacy employees from different cities in Poland
Gu et al.	2019	Zinc deficiency and epigenetics
Hamadi et al.	2025	Potential Effect of Spirulina Extracts on Serum Iron Reduction: Possible Application in Cancer Treatment
Moesgaard et al.	2001	The Need for Speciation to Realise the Potential of Selenium
Kumar	2016	Copper deficiency myeloneuropathy
Guarnieri et al.	1984	Muscle cathepsin D activity, and RNA, DNA and protein content in maintenance hemodialysis patients
US20240382518A1 (en)	2024-11-21	Pharmaceutical composition and health functional food for prevention or treatment of osteoarthritis
Chaitanya et al.	2021	Cause for Reduced Longevity in
Barford et al.	1956	Low protein diets and sulphur metabolism.
Dunn et al.	2016	Testing the Ability of Selenium and Vitamin E to Prevent Prostate Cancer in a Large Randomized Phase III Clinical Trial: The Selenium and Vitamin E Cancer Prevention Trial
Wessels	2019	Epigenetics and Minerals: An Overview

Legal Events

Date	Code	Title	Description
2009-08-10	EEER	Examination request
2011-08-10	FZDE	Discontinued